Urinary me

Urinary metabolomics provide insights into coronary artery disease in individuals with type 1 diabetes.

BACKGROUND Type 1 diabetes increases the risk of coronary artery disease (CAD). High-throughput metabolomics may be utilized to identify metabolites associated with disease, thus, providing insight into disease pathophysiology, and serving as predictive markers in clinical practice. Urine is less tightly regulated than blood, and therefore, may enable earlier discovery of disease-associated markers. We studied urine metabolomics in relation to incident CAD in individuals with type 1 diabetes. METHODS We prospectively studied CAD in 2501 adults with type 1 diabetes from the Finnish Dia...

Serum Proteins Predict Treatment-Related Cardiomyopathy in Survivors of Childhood Cancer

A risk model, developed on the basis of the differential expression of serum proteins in subclinical cardiomyopathy, accurately discriminated the risk for severe cardiomyopathy among survivors of childhood cancer, according to a study published in JA...

FDA Approves Drug for Heart Disorder Caused by Transthyretin-Mediated Amyloidosis

The US Food and Drug Administration (FDA) has approved acoramidis (Attruby) to treat adults with cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) to reduce death and hospitalisation related to heart problems. Aco...


Sixty Seconds Science


Spotify episodes

Apple podcasts

Google podcasts

Partner

Search:
Date
Filters:
How to imp
11:37

How to improve immunization in children and adolescents?

Presenter: Robert Jacobson
Respiratory
CHEST 2024
New develo
9:19

New developments in neurendocrine tumours

Presenter: Jennifer Chan
Oncology
ESMO 2024
New direct
6:23

New directions in Asthma and COPD

Presenter: Monica Kraft
Respiratory
CHEST 2024
Comparison
10:54

Comparison of GINA and EPR-4 Asthma Guidelines

Presenter: Shahid Sheikh
Respiratory
CHEST 2024
Importance
5:30

Importance of Vaccinations for Patients With Pulmonary Conditions

Presenter: Shekhar Ghamande
Respiratory
CHEST 2024
Breathing
12:30

Breathing Easier: The Evolution and Future of Asthma Care

Presenter: Sandhya Khurana
Respiratory
CHEST 2024
How to man
10:52

How to manage acute PE? Follow the five D!

Presenter: Bhavinkumar Dalal
Respiratory
CHEST 2024
Update in
10:13

Update in Vaccines for RSV, COVID, Influenza

Presenter: Aanchal Kapoor
Respiratory
CHEST 2024
Duchenne M
8:18

Duchenne Muscular Dystrophy, Then and Now: Lessons from Respiratory Medicine

Presenter: David J. Birnkrant
Respiratory
CHEST 2024
Advanced M
12:42

Advanced Management Strategies in Severe Asthma and COPD

Presenter: Muhammad Adrish
Respiratory
CHEST 2024
CHEST Guid
4:45

CHEST Guidelines on Biologics for Severe Asthma: Evidence, Recommendations, and Clinical Implications

Presenter: Megan Conroy
Respiratory
CHEST 2024
The role o
6:00

The role of LABA/LAMA and triple therapy for patients with COPD in GOLD Group E

Presenter: Nicola Hanania
Respiratory
CHEST 2024
Hemodynami
3:55

Hemodynamic Assessment in Pulmonary Arterial Hypertension - Obtaining the Most Out of Right Heart Catheterization

Presenter: Adriano Tonelli
Respiratory
CHEST 2024
Portopulmo
5:15

Portopulmonary Hypertension: How Should We Think About it?

Presenter: Hilary Dubrock
Respiratory
CHEST 2024
Beyond Bro
4:46

Beyond Bronchodilators: Bronchoscopic Management of COPD

Presenter: Jonathan Kurman
Respiratory
CHEST 2024
Evaluation
10:56

Evaluation and Management of VTE in Pregnancy

Presenter: Lisa Moores
Respiratory
CHEST 2024
Carfilzomi
6:49

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor

Presenter: Saad Z. Usmani
Hematology
Inhibition
6:22

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease: Results from the Phase 3 Cardinal Study

Presenter: Alexander Röth
Hematology
The QUAZAR
8:20

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia in First Remission

Presenter: Andrew H. Wei
Hematology
Validation
7:11

Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing

Presenter: David A. Williams
Hematology
A Randomiz
4:40

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk First Relapse of B-ALL in Children and Adolescents/Young Adults Demonstrates Superior Efficacy and Tolerability of Blinatumomab

Presenter: Patrick A. Brown
Hematology
CLARIFY -
7:07

CLARIFY - In stable coronary disease, patients with angina and prior myocardial infarction have a poor prognosis despite adherence to guideline recommanded therapies. Final 5-year results from the CLARIFY study

Presenter: Emmanuel Sorbets
Cardiology
SWEDEHEART
5:26

SWEDEHEART: Secondary prevention medication after coronary artery bypass surgery and long-term mortality: A longitudinal population-based study from the SWEDEHEART registry

Presenter: Erik Bjoerklund
Cardiology
ICD use in
4:31

ICD use in HF - Association between implantable cardioverter-defibrillator use for primary prevention and mortality: a prospective propensity-score matched study

Presenter: Benedikt Schrange
Cardiology
PURE: Impa
10:51

PURE: Impact of modifiable risk factors on cardiovascular disease and mortality

Presenter: Salim Yusuf
Cardiology
RAPIDTnT:
5:37

RAPIDTnT: A randomised trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: the Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T

Presenter: Derek Chew
Cardiology
ENTRUST-AF
7:45

ENTRUST-AF PCI - Edoxaban-based versus vitamin-K-antagonist-based anti-thrombotic regimen following successful coronary stenting in atrial fibrillation patients

Presenter: Andreas Goette
Cardiology
POPular Ge
6:51

POPular Genetics - Genotype-guided oral P2Y12-inhibition in patients with St-segment elevation myocardial infarction undergoing primary PCI : a randomized, open-label, multicenter trial

Presenter: Jurrien M. Ten Berg
Cardiology
Combined e
5:03

Combined effect of lower LDL-C and lower SBP on the lifetime risk od cardiovascular disease

Presenter: Brian A. Ference
Cardiology
AFIRE - Ri
4:47

AFIRE - Rivaroxaban monotherapy versus dual therapy in patients with atrial fibrillation and stable coronary artery disease

Presenter: Satoshi Yasuda
Cardiology
GALACTIC -
7:23

GALACTIC - Goal-directed AfterLoad Reduction in Acute Congestive Cardiac Decompensation: a randomized controlled trial

Presenter: Christian Eugen Mueller
Cardiology
Salt subst
5:16

Salt substitution and community-wide reduction in blood pressure and hypertension incidence

Presenter: J. Jaime Miranda
Cardiology
The import
11:22

The importance of the anterior interface in eye surgery

Presenter: Marie-José Tassignon
Internal Medicine
Haematolog
17:26

Haematology is at the forefront - interview with EHA President

Presenter: Antonio Almeida
Oncology
Overall Su
13:30

Overall Survival Results of KEYNOTE-564

Presenter: Stefan N. Symeonides
Oncology
General as
1:18

General aspects of the ESH2023 Hypertension Guidelines - What are the major changes?

Presenter: Michel Burnier
Cardiology
How shall
1:23

How shall be treat hypertension and look at cardiac risk factors when we consider proper treatment?

Presenter: Konstantinos Tsioufis
Cardiology
How to tre
1:06

How to treat patients optimally with chronic coronary syndromes in 2023?

Presenter: Luis Henrique Gowdak
Overall Su
20:13

Overall Survival Results of KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma

Presenter: David F. McDermott
Oncology
How novel
1:07

How novel AI model may help physicians distinguish and identify prefibrotic primary myelofibrosis from essential thrombocythemia?

Presenter: Andrew Srisuwananukorn
Hematology
The future
1:10

The future of Multiple Myeloma management

Presenter: Xavier Leleu
Hematology
Benefits o
1:01

Benefits of myeloma regimens in the real world fall well short of trials

Presenter: Alissa Visram
Hematology
The prefer
0:57

The preferred treatment of hypertension with RAAS blockade inhibitors

Presenter: Martin Strauss
Cardiology
What clini
1:16

What clinicians should know about the new ESH guideline regarding hypertension in women?

Presenter: Renata Cifkova
Cardiology
How to man
1:00

How to manage isolated systolic hypertension in the young?

Presenter: Paolo Palatini
Cardiology
Blood pres
1:34

Blood pressure monitoring in general and what we can do to encourage people.

Presenter: Neil Poulter
Cardiology
How to man
1:08

How to manage masked and masked uncontrolled hypertension?

Presenter: Paolo Palatini
Cardiology
ESMO 2023
1:13

ESMO 2023 Scientific Chair's welcome and invitation to next year's ESMO Congress

Presenter: Silke Gillessen
Oncology